Novo Nordisk A/S’s decision to stop making insulin pens will narrow treatment options for children with diabetes unless ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...

The REAL8 basket study showed Sogroya (somapacitan) was non-inferior to Norditropin (somatropin) in improving yearly growth ...

NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular ...

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...